{"id":"NCT00503399","sponsor":"Eli Lilly and Company","briefTitle":"Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis","officialTitle":"Comparison of the Effects of Teriparatide With Those of Risedronate on Lumbar Spine vBMD in Glucocorticoid-Induced Osteoporosis in Men","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-07","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2007-07-18","resultsPosted":"2011-11-08","lastUpdate":"2012-03-13"},"enrollment":92,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Osteoporosis"],"interventions":[{"type":"DRUG","name":"Teriparatide","otherNames":["LY333334","Forteo","Forsteo"]},{"type":"DRUG","name":"Risedronate","otherNames":["Actonel"]}],"arms":[{"label":"Teriparatide","type":"EXPERIMENTAL"},{"label":"Risedronate","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of this study is to test the hypothesis that teriparatide is superior to the active comparator in the change from baseline to 18 months of lumbar spine volumetric trabecular bone mineral density (BMD) in males with glucocorticoid-induced osteoporosis.","primaryOutcome":{"measure":"Change From Baseline in Lumbar Spine Volumetric Trabecular Bone Mineral Density (BMD) by Quantitative Computerized Tomography (QCT) at 18 Months","timeFrame":"Baseline, 18 months","effectByArm":[{"arm":"Teriparatide","deltaMin":12.28,"sd":3.16},{"arm":"Risedronate","deltaMin":2.94,"sd":3.14}],"pValues":[]},"eligibility":{"minAge":"25 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":13,"countries":["Germany","Greece","Italy","Spain"]},"refs":{"pmids":["23322362","23149277"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":45},"commonTop":["Influenza","Arthralgia","Oedema peripheral","Nausea","Nasopharyngitis"]}}